The Macular Society has welcomed final approval of a new, longer-lasting drug to treat wet age-related macular degeneration.
The Society is urging the NHS to introduce the new drug, Eylea, quickly to help meet the enormous demand for wet AMD treatment.
The National Institute of Health and Care Excellence has issued final guidance on the use of Eylea for wet AMD today having fast-tracked it through the appraisal process.
Age-related macular degeneration (AMD) affects the central vision and is the biggest cause of sight loss in the UK. More people are affected as our population ages. See full article on Vision 2020 website.